NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
Clinical Trials
54 trialsNCT06514898 2026-04-03
MATCHPOINT
University of Florida
Phase 1 Active not recruiting
NCT07374029 2026-04-03
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT06254326 2026-03-09
ADAGiO
University of Florida
Phase 1 Active not recruiting
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT03334305 2026-01-29
ACTION
University of Florida
Phase 1 Terminated
NCT07377435 2026-01-29
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT05307835 2025-12-02
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Active not recruiting
NCT03396575 2025-10-29
BRAVO
University of Florida
Phase 1 Terminated
NCT06799026 2025-09-02
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center
Phase 1 Recruiting
NCT04963413 2025-08-06
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
Phase 1 Terminated
NCT04040231 2025-05-13
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
NCT03538314 2024-08-22
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Ultimovacs ASA
Phase 1 Completed
NCT05238558 2023-09-21
Safety and Immune Response to FMPV-1
Hubro Therapeutics AS
Phase 1 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT00070070 2022-10-12
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT04861948 2022-10-04
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT02250014 2022-02-09
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
University of Colorado, Denver
Phase 1 Completed
NCT03645148 2021-11-16
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
Zhejiang Provincial People's Hospital
Phase 1 Completed
NCT03662815 2021-11-16
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT04810910 2021-11-16
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Zhejiang Provincial People's Hospital
Phase 1 Unknown
NCT04864379 2021-04-28
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT02411786 2021-02-04
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
University of Wisconsin, Madison
Phase 1 Completed
NCT03615404 2021-01-28
ATTAC-P
Duke University
Phase 1 Completed
NCT01536054 2020-03-27
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT02019524 2020-03-18
J65
San Antonio Military Medical Center
Phase 1 Completed
NCT02383212 2020-01-27
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00834665 2019-10-23
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
University of Pennsylvania
Phase 1 Completed
NCT00383994 2019-07-31
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03392545 2019-07-11
InSituVac1
Beijing Tiantan Hospital
Phase 1 Unknown
NCT00002787 2019-05-06
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT00600002 2018-06-11
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT00477815 2018-05-14
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT00952237 2018-04-25
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT02130869 2017-12-22
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00001512 2017-07-02
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00471471 2017-06-22
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 1 Completed
NCT00631072 2017-06-09
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00027807 2016-02-17
Biological Therapy in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00569296 2015-03-25
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
Roger Williams Medical Center
Phase 1 Terminated
NCT01081808 2015-03-25
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
Roger Williams Medical Center
Phase 1 Terminated
NCT01403285 2014-05-19
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Immatics Biotechnologies GmbH
Phase 1 Terminated
NCT00088933 2014-03-31
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00009958 2013-05-16
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00512889 2013-03-01
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00028496 2013-01-25
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed